Malanil® Paediatric Tablets – Expands the antimalarial chemoprophylaxis options for children
Keywords: Malanil® Paediatric Tablets, antimalarial chemoprophylaxis
AbstractIdeally, infants and children under 5 years of age should not travel to malaria areas.1 However, if travel to a malaria risk area is essential, then antimalarial chemoprophylaxis is indicated.1 The paediatric combination of atovaquone and proguanil is a welcome addition to the antimalarial chemoprophylaxis options available for use in children. Malanil® Paediatric Tablets contain 62.5 mg atovaquone and 25 mg proguanil per tablet.2 The product is indicated for the prophylaxis of drug sensitive and drug resistant Plasmodium falciparum malaria.2 Official local and international malaria chemoprophylaxis guidelines should be consulted at least two weeks before intended travel to establish the risk of malaria in a particular area.2
New Product Focus
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.